Table 3. Clinicopathological characteristics and proportion of PD-1+ leukocytes, PD-L1+ leukocytes and PD-L1+ HRS cells in the treated group*.
| Case | Calendar yeara |
Time between biopsiesb | Agec | EBV statusd | Biopsy location (primary/relapse) | Diagnosis (primary/relapse) | PD-1+ leukocytes (%) | PD-L1+ leukocytes (%) | PD-L1 +HRS (%) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Relapse | Primary | Relapse | Primary | Relapse | |||||||
| 1 | 2005 | 20 | 26 | NA | abdomen/abdomen | MC/MC | 1 | 3 | 19 | 19 | 100 | 100 |
| 2 | 2006 | 112 | 41 | NA | neck/neck | NS/NS | 0 | 1 | 27 | 40 | 100 | 100 |
| 3 | 2010 | 40 | 35 | NA | neck/mediastinum | NS/NS | 0 | 3 | 37 | 75 | 100 | 100 |
| 4 | 2010 | 76 | 12 | NA | neck/mediastinum | MC/MC | 0 | 8 | 41 | 48 | 100 | 70 |
| 5 | 2015 | 8 | 26 | negative | neck/neck | NS/NS | 5 | 4 | 45 | 57 | 100 | 100 |
| 6 | 1997 | 31 | 31 | NA | neck/neck | NS/NS | 0 | 1 | 40 | 31 | 95 | 100 |
| 7 | 2001 | 23 | 37 | NA | neck/neck | NS/NS | 0 | 2 | 16 | 20 | 90 | 90 |
| 8 | 1991 | 17 | 24 | NA | inguinal/NA | NS/NS | 0 | 1 | 25 | 30 | 90 | 70 |
| 9 | 2000 | 10 | 16 | NA | neck/neck | NS/NS | 1 | 1 | 31 | 29 | 90 | 90 |
| 10 | 2009 | 41 | 25 | NA | neck/neck | NS/NS | 0 | 3 | 34 | 50 | 90 | 95 |
| 11 | 2015 | 7 | 32 | negative | neck/neck | NS/NS | 3 | 5 | 38 | 12 | 90 | 90 |
| 12 | 1998 | 45 | 46 | NA | neck/neck | NS/MC | 0 | 3 | 60 | 43 | 85 | 50 |
| 13 | 2003 | 36 | 45 | NA | neck/neck | NS/NS | 1 | 0 | 26 | 29 | 80 | 80 |
| 14 | 1984 | 136 | 32 | NA | neck/paraaortal | MC/MC | 2 | 1 | 33 | 34 | 80 | 80 |
| 15 | 2007 | 15 | 55 | NA | inguinal/inguinal | MC/MC | 1 | 1 | 35 | 43 | 80 | 85 |
| 16 | 1980 | 146 | 36 | negative | neck/neck | NS/NS | 3 | 11 | 22 | 53 | 75 | 90 |
| 17 | 1981 | 72 | 27 | NA | neck/neck | NS/NS | 1 | 3 | 4 | 17 | 70 | 90 |
| 18 | 2009 | 8 | 65 | NA | axilla/NA | NS/NS | 0 | 1 | 21 | 26 | 65 | 75 |
| 19 | 2014 | 12 | 16 | NA | axilla/inguinal | NS/NS | 3 | 7 | 25 | 58 | 60 | 70 |
| 20 | 2011 | 8 | 33 | NA | neck/neck | NS/NS | 4 | 1 | 10 | 37 | 50 | 80 |
| 21 | 1981 | 64 | 16 | NA | NA/NA | MC/MC | 0 | 0 | 18 | 47 | 45 | 100 |
| 22 | 1989 | 43 | 75 | NA | inguinal/inguinal | NS/NS | 3 | 0 | 10 | 18 | 40 | 70 |
| 23 | 2014 | 17 | 64 | negative | inguinal/inguinal | NS/NS | 32 | 8 | 18 | 20 | 35 | 70 |
| 24 | 2005 | 7 | 76 | positive | neck/neck | MC/MC | 0 | 1 | 46 | 34 | 30 | 35 |
| 25 | 1986 | 36 | 29 | NA | mediastinum/neck | NS/NS | 8 | 24 | 8 | 17 | 15 | 40 |
| 26 | 1994 | 49 | 13 | NA | neck/lung | NS/NS | 12 | 2 | 8 | 7 | 10 | 40 |
| 27 | 1989 | 20 | 12 | NA | axilla/axilla | NS/NS | 0 | 5 | 4 | 11 | 0 | 80 |
| 28 | 2011 | 68 | 68 | NA | neck/neck | NS/NS | 4 | 6 | 10 | 19 | 0 | 100 |
| 29 | 1990 | 53 | 42 | NA | abdomen/NA | MC/MC | 1 | 16 | 11 | 9 | 0 | 10 |
| 30 | 1981 | 48 | 39 | NA | NA/NA | MC/MC | 3 | 3 | 23 | 73 | 0 | 80 |
aYear of primary diagnosis of cHL.
bTime elapsed between biopsy 1 and biopsy 2 in months.
cAge at primary diagnosis of cHL.
dEBV status determined with EBER at primary biopsy.
PD-1 = Programmed death receptor 1, PD-L1 = Programmed death ligand 1, HRS = Hodgkin Reed-Sternberg, MC = Mixed cellularity, NS = Nodular sclerosis, EBV = Epstein-Barr virus, NA = Not available.
*Sorted according to expression of PD-L1 by HRS cells.